Recent Quotes
My Watchlist
Indicators
EL&P Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

BridgeBio Pharma, Inc. - Common Stock (NQ:BBIO)

72.01 +0.29 (+0.40%)
Streaming Delayed Price Updated: 1:00 PM EST, Nov 28, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 524,469
Open 71.06
Bid (Size) 71.30 (300)
Ask (Size) 72.49 (300)
Prev. Close 71.72
Today's Range 70.93 - 72.28
52wk Range 25.34 - 72.28
Shares Outstanding 160,500,999
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
BridgeBio (BBIO) Q3 2025 Earnings Call Transcript ↗
BridgeBio (BBIO) Q3 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
BridgeBio to Participate in December Investor Conferences
From BridgeBio Pharma, Inc.
Via GlobeNewswire

Performance

YTD
+155.4%
+155.4%
1 Month
+8.1%
+8.1%
3 Month
+39.1%
+39.1%
6 Month
+110.2%
+110.2%
1 Year
+165.8%
+165.8%

More News

Read More
News headline image
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For October 29, 2025 ↗
Via Benzinga
News headline image
Earnings Outlook For BridgeBio Pharma ↗
Via Benzinga
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
Via Benzinga
News headline image
Healthcare Sector Navigates Turbulent Waters: Innovation Surges Amidst Political Headwinds
Via MarketMinute
Topics Artificial Intelligence Economy Government
News headline image
Acoramidis Significantly Reduces All-cause Mortality in the Overall ATTR-CM Variant and V142I (V122I) Populations
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
Biotech Sector Soars: Promising Drug Trials Ignite Investor Confidence and Spark Market Rally
Via MarketMinute
Topics Artificial Intelligence Intellectual Property
News headline image
BridgeBio to Participate in November Investor Conferences
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
BridgeBio to Present Data from the Overall ATTR-CM Variant and V142I (V122I) Populations from ATTRibute-CM at the AHA Scientific Sessions 2025
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
Alnylam Stock Has Already Doubled In 2025. Why It Could Rocket Again On Earnings. ↗
Via Investor's Business Daily
News headline image
BridgeBio Pharma (NASDAQ:BBIO) Q3 2025 Revenue Beat Overshadowed by Widened Loss ↗
Via Chartmill
News headline image
BridgeBio Reports Third Quarter 2025 Financial Results and Business Updates
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
BridgeBio's Investigation Drug Outperforms Standard Therapy In Rare Calcium Disorder ↗
Via Benzinga
News headline image
BridgeBio Shares Second Positive Late-Stage Study Result In A Week – Calcium Disorder Drug Trial Yields Positive Results ↗
Via Stocktwits
News headline image
BridgeBio Pharma Lines Up Another 'Domino' As It Nears A Record High ↗
Via Investor's Business Daily
News headline image
BridgeBio Reports Positive Phase 3 Topline Results for Encaleret in Patients with Autosomal Dominant Hypocalcemia Type 1
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
Via Benzinga
News headline image
BridgeBio to Report Phase 3 Results for Encaleret in ADH1 CALIBRATE Study on Wednesday, October 29th
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
Janus Henderson, Avidity Biosciences, BridgeBio Pharma And Other Big Stocks Moving Higher On Monday ↗
Via Benzinga
News headline image
BBIO Stock Soars After Experimental Drug Shows Improvement In Inherited Muscle Disorder In Late-stage Trial ↗
Via Stocktwits
News headline image
BridgeBio Reports Positive Phase 3 Results for Small Molecule BBP-418 in LGMD2I/R9 FORTIFY Study
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
BridgeBio to Report Phase 3 Results for Small Molecule BBP-418 in LGMD2I/R9 FORTIFY Study, along with Third Quarter 2025 Financial Results Next Week
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From BridgeBio Pharma, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is BridgeBio Pharma, Inc. - Common Stock publicly traded?
Yes, BridgeBio Pharma, Inc. - Common Stock is publicly traded.
What exchange does BridgeBio Pharma, Inc. - Common Stock trade on?
BridgeBio Pharma, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for BridgeBio Pharma, Inc. - Common Stock?
The ticker symbol for BridgeBio Pharma, Inc. - Common Stock is BBIO on the Nasdaq Stock Market
What is the current price of BridgeBio Pharma, Inc. - Common Stock?
The current price of BridgeBio Pharma, Inc. - Common Stock is 72.01
When was BridgeBio Pharma, Inc. - Common Stock last traded?
The last trade of BridgeBio Pharma, Inc. - Common Stock was at 11/28/25 01:00 PM ET
What is the market capitalization of BridgeBio Pharma, Inc. - Common Stock?
The market capitalization of BridgeBio Pharma, Inc. - Common Stock is 11.56B
How many shares of BridgeBio Pharma, Inc. - Common Stock are outstanding?
BridgeBio Pharma, Inc. - Common Stock has 12B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.